Unity Biotechnology (UBX) Stock Price, News & Analysis

Company Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.97 to $1.03
• 50-Day Range: $0.88 to $2.26
• 52-Week Range: $0.85 to $3.10
• Volume: 52,749 shs
• Average Volume: 117,044 shs
• Market Capitalization: $16.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.33
• Consensus Rating: Buy

Unity Biotechnology Stock Analysis - MarketRank™

Unity Biotechnology scored higher than 85% of companies evaluated by MarketBeat, and ranked 122nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Unity Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Unity Biotechnology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Unity Biotechnology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Unity Biotechnology has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.62% of the float of Unity Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Unity Biotechnology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unity Biotechnology has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Unity Biotechnology does not currently pay a dividend.

Dividend Growth

Unity Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

4.62% of the float of Unity Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Unity Biotechnology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Unity Biotechnology has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Unity Biotechnology has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Unity Biotechnology this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,405.00 in company stock.

Percentage Held by Insiders

Only 5.80% of the stock of Unity Biotechnology is held by insiders.

Percentage Held by Institutions

Only 29.49% of the stock of Unity Biotechnology is held by institutions.

UBX Stock Analysis - Frequently Asked Questions

How have UBX shares performed this year?

Unity Biotechnology's stock was trading at $0.9764 at the beginning of the year. Since then, UBX shares have decreased by 0.6% and is now trading at $0.9710.
View the best growth stocks for 2025 here.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02.

When did Unity Biotechnology's stock split?

Unity Biotechnology's stock reverse split on the morning of Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Unity Biotechnology IPO?

Unity Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's top institutional investors include SeaCrest Wealth Management LLC (0.16%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg, Lynne Marie Sullivan and Alexander Hieu Nguyen.
View institutional ownership trends.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Unity Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia Oyj (NOK).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 4/15/2025
• Next Earnings (Estimated): 4/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UBX
• CIK: 1463361
• Web: www.unitybiotechnology.com
• Phone: (650) 416-1192
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.33
• High Stock Price Target: $8.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +449.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -119.70%
• Return on Assets: -45.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.45
• Quick Ratio: 3.45

Sales & Book Value

• Annual Sales: $240,000.00
• Price / Sales: 68.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.69 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 16,868,000
• Free Float: 15,873,000
• Market Cap: $16.36 million
• Optionable: Optionable
• Beta: 1.30